Effect of ON101 Topical Cream on Infected Diabetic Foot Ulcer: A Case Series in the US Elderly Patients.

5 Key Takeaways from This Clinical Poster

---

• Discover the real-world clinical performance of ON101 topical cream in an elderly US population (mean age 72.3 years) with mildly infected diabetic foot ulcers (Wagner Grade 2).
• Learn how ON101 promotes fast wound closure within a short timeframe of 6 to 9 weeks and achieves a marked reduction in wound size.
• Understand how ON101 effectively facilitates healing even in high-risk, complex patients burdened with peripheral arterial disease (PAD), long-standing diabetes (>10 years), and a history of amputation (3 out of 4 cases).
• Confirm that the ON101 treatment protocol (applied twice daily for up to 8 weeks alongside systemic antibiotics) is safe, well-tolerated, and produces no adverse effects, demonstrating high patient compliance in a real-world US clinical setting.
• l See how subjects using ON101 reported a decrease in pain sensation, suggesting that this treatment not only promotes healing but also enhances limb preservation and overall quality of life for high-risk elderly populations.

 

Target Audience for This Poster

---

• Podiatrists (DPM) and Foot/Ankle Surgeons
• Wound Care Specialists and Clinical Nurses
• Geriatricians
• Endocrinologists / Metabolic Specialists

Methods

---

• Design: Prospective case series (n=4)
• Site: Wound Clinic at Casa Colina Hospital
• Inclusion Criteria:
  • Age > 60,  Wagner Grade 2DFU with mild infection (IDSA Grade 2)
  • Concurrent systemic antibiotics
• Exclusion Criteria: Dialysis or inadequate perfusion
• Treatment Protocol:
  • ON101 applied twice daily for up to 8 weeks
  • Weekly clinic assessment and image documentation
• Perfusion Assessment: ABI / TBI / Pedal pulse
• Outcome Measures:
  • Wound area reduction
  • Healing time
  • Safety (adverse events)

 

Executive Summary

---

This case series highlights ON101’s potential as an effective adjunctive treatment for iDFUs in elderly, PAD-complicated patients. Despite advanced age (mean 72.3 yrs), amputation history (3/4), and long-standing diabetes (>10 years), ON101 facilitated:

• Fast wound closure (6-9 weeks)
• Marked wound size reduction
• No adverse effects
• High patient compliance in real-world US clinical setting
• Subjects reported decreased pain sensation

These findings suggest ON101 can enhance limb preservation and quality of life even in high-risk elderly wound populations.

 

Conclusion

---

ON101 was safe, well-tolerated, and clinically effective in elderly patients with infected DFUs, promoting healing even in complex cases with amputation history and PAD.